Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD B POWELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1023103702
CMS profile
819362
Location
NEW PORT RICHEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,086.41

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,289.60 8
Food and Beverage $796.81 7

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,656.40 5
Biogen, Inc. $1,413.37 9
Electromed, Inc. $16.64 1

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD B POWELL

NPI 1023103702 · CMS profile ID 819362

Allopathic & Osteopathic Physicians / Internal Medicine

NEW PORT RICHEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023103702?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023103702?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023103702?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1023103702?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $3,086.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Electromed, Inc. $16.6411/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 977386233 CMS
Biogen, Inc. $50.4010/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012143397 CMS
Biogen, Inc. $62.5510/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012152844 CMS
Biogen, Inc. $62.5510/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012234969 CMS
Biogen, Inc. $342.8410/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012234973 CMS
Biogen, Inc. $45.2310/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012256455 CMS
Biogen, Inc. $73.3310/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012275629 CMS
Biogen, Inc. $120.3310/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012188375 CMS
Biogen, Inc. $409.9010/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012237051 CMS
Biogen, Inc. $246.2410/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012271487 CMS
ModernaTX, Inc. $690.2101/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981513 CMS
ModernaTX, Inc. $40.0001/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981517 CMS
ModernaTX, Inc. $267.7101/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981521 CMS
ModernaTX, Inc. $247.4701/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981525 CMS
ModernaTX, Inc. $411.0101/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981529 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,998.99 5
PY2020 $39.93 2
PY2023 $3,086.41 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $123,379.85 19
PY2024 Principal investigator $519,613.32 181
PY2023 Principal investigator $3,705,517.67 2,390
PY2022 Principal investigator $2,801,811.98 590
PY2021 Principal investigator $422,228.81 39
PY2020 Principal investigator $83,061.46 21
PY2019 Principal investigator $408,254.19 140

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

140 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $737.43 12/31/2019 Non-covered Recipient Entity
Meridien Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684985455
Principal investigator 1 AstraZeneca UK Limited $951.57 12/31/2019 Non-covered Recipient Entity
Meridien Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685000633
Principal investigator 1 Amgen Inc. $1,650.00 12/24/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH
GOULD No dispute reported 06/30/2026 675778163
Principal investigator 1 Eisai Inc. $1,500.00 12/23/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525209
Principal investigator 1 Eisai Inc. $1,000.00 12/23/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525211
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,197.50 12/12/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-303 No dispute reported 06/30/2026 656018125
Principal investigator 1 AbbVie, Inc. $67.50 12/11/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586563
Principal investigator 1 AbbVie, Inc. $10,444.03 11/27/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586565
Principal investigator 1 Eisai Inc. $2,766.00 11/26/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525217
Principal investigator 1 Eisai Inc. $1,600.00 11/26/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525219
Principal investigator 1 Eisai Inc. $2,766.00 11/26/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525221
Principal investigator 1 Eisai Inc. $1,600.00 11/26/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525223
Principal investigator 1 Eisai Inc. $1,648.00 11/26/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525225
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 11/25/2019 Non-covered Recipient Entity
Meridien Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691606891
Principal investigator 1 Avanir Pharmaceuticals, Inc. $3,545.50 11/21/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-303 No dispute reported 06/30/2026 656018123
Principal investigator 1 AbbVie, Inc. $210.60 11/08/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586567
Principal investigator 1 AbbVie, Inc. $105.30 10/31/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586559
Principal investigator 1 AbbVie, Inc. $3,986.75 10/30/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586557
Principal investigator 1 Eisai Inc. $1,648.00 10/29/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525215
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,645.80 10/18/2019 Non-covered Recipient Entity
Meridien Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684985433
Principal investigator 1 AbbVie, Inc. $100.00 10/15/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586561
Principal investigator 1 Eisai Inc. $2,981.00 10/03/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525099
Principal investigator 1 Eisai Inc. $1,190.00 10/03/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525101
Principal investigator 1 Eisai Inc. $1,319.00 10/03/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525103
Principal investigator 1 Eisai Inc. $1,554.00 10/03/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525105
Principal investigator 1 AbbVie, Inc. $7,795.70 09/30/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586553
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,847.50 09/27/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-303 No dispute reported 06/30/2026 656018119
Principal investigator 1 SANOFI US SERVICES INC. $700.00 09/19/2019 Non-covered Recipient Entity
Meridien Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691569553
Principal investigator 1 Eisai Inc. $1,234.00 09/17/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525123
Principal investigator 1 AbbVie, Inc. $105.30 09/10/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586555
Principal investigator 1 AbbVie, Inc. $13,596.13 08/29/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586551
Principal investigator 1 Eisai Inc. $2,981.00 08/27/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525107
Principal investigator 1 SANOFI US SERVICES INC. $100.00 08/22/2019 Non-covered Recipient Entity
Meridien Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691572019
Principal investigator 1 Eisai Inc. $2,496.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525109
Principal investigator 1 Eisai Inc. $4,265.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525111
Principal investigator 1 Eisai Inc. $1,600.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525113
Principal investigator 1 Eisai Inc. $3,802.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525115
Principal investigator 1 Eisai Inc. $2,496.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525117
Principal investigator 1 Eisai Inc. $1,190.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525119
Principal investigator 1 Eisai Inc. $1,190.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525121
Principal investigator 1 Eisai Inc. $4,265.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525125
Principal investigator 1 Eisai Inc. $1,600.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525127
Principal investigator 1 Eisai Inc. $3,802.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525129
Principal investigator 1 Eisai Inc. $1,600.00 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525131
Principal investigator 1 Eisai Inc. $173.90 08/15/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525213
Principal investigator 1 SANOFI US SERVICES INC. $1,725.00 08/15/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691571631
Principal investigator 1 SANOFI US SERVICES INC. $3,532.00 07/22/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691569653
Principal investigator 1 AbbVie, Inc. $2,812.65 07/15/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586547
Principal investigator 1 OPKO Pharmaceuticals, LLC $7,912.50 07/11/2019 Non-covered Recipient Entity
Meridien Research, Inc.
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 704260233
Principal investigator 1 AbbVie, Inc. $200.00 07/10/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586549
Principal investigator 1 SANOFI US SERVICES INC. $100.00 06/27/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691557457
Principal investigator 1 SANOFI US SERVICES INC. $1,400.00 06/27/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691557461
Principal investigator 1 AbbVie, Inc. $12,816.03 06/20/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586537
Principal investigator 1 Avanir Pharmaceuticals, Inc. $3,778.00 06/20/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-302 No dispute reported 06/30/2026 656018107
Principal investigator 1 Avanir Pharmaceuticals, Inc. $5,771.50 06/20/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-303 No dispute reported 06/30/2026 656018109
Principal investigator 1 SANOFI US SERVICES INC. $5,762.75 06/20/2019 Non-covered Recipient Entity
Meridien Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691559413
Principal investigator 1 AbbVie, Inc. $350.00 06/11/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586539
Principal investigator 1 Eisai Inc. $913.00 06/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525133
Principal investigator 1 Eisai Inc. $900.00 06/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525135
Principal investigator 1 Eisai Inc. $962.00 06/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525137
Principal investigator 1 Eisai Inc. $962.00 06/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525139
Principal investigator 1 Eisai Inc. $1,382.00 06/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525141
Principal investigator 1 Eisai Inc. $1,657.00 06/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525143
Principal investigator 1 Eisai Inc. $1,234.00 06/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525145
Principal investigator 1 Eisai Inc. $1,706.00 06/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702525147
Principal investigator 1 Avanir Pharmaceuticals, Inc. $4,242.50 06/06/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-303 No dispute reported 06/30/2026 656018105
Principal investigator 1 AbbVie, Inc. $200.00 06/05/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586541
Principal investigator 1 AbbVie, Inc. $105.30 06/05/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586543
Principal investigator 1 AbbVie, Inc. $500.00 06/04/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586545
Principal investigator 1 SANOFI US SERVICES INC. $1,113.00 05/30/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691558579
Principal investigator 1 AbbVie, Inc. $2,927.80 05/17/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586535
Principal investigator 1 Eisai Inc. $1,658.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525171
Principal investigator 1 Eisai Inc. $382.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525173
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525175
Principal investigator 1 Eisai Inc. $1,658.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525177
Principal investigator 1 Eisai Inc. $1,120.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525179
Principal investigator 1 Eisai Inc. $1,859.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525181
Principal investigator 1 Eisai Inc. $605.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525183
Principal investigator 1 Eisai Inc. $382.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525185
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525187
Principal investigator 1 Eisai Inc. $1,600.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525189
Principal investigator 1 Eisai Inc. $1,120.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525191
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525193
Principal investigator 1 Eisai Inc. $3,934.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525195
Principal investigator 1 Eisai Inc. $2,002.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525197
Principal investigator 1 Eisai Inc. $1,600.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525199
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525201
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525203
Principal investigator 1 Eisai Inc. $1,859.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525205
Principal investigator 1 Eisai Inc. $605.00 05/07/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525207
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,000.00 05/02/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-302 No dispute reported 06/30/2026 656018101
Principal investigator 1 Avanir Pharmaceuticals, Inc. $17,682.50 05/02/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-302 No dispute reported 06/30/2026 656018103
Principal investigator 1 Novo Nordisk AS $3,377.16 04/30/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH
NN9535-4270 No dispute reported 06/30/2026 692464381
Principal investigator 1 Novo Nordisk AS $1,000.00 04/30/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH
NN9535-4270 No dispute reported 06/30/2026 692464383
Principal investigator 1 Novo Nordisk AS $500.00 04/30/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH
NN9535-4270 No dispute reported 06/30/2026 692464385
Principal investigator 1 SANOFI US SERVICES INC. $2,756.00 04/23/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691555113
Principal investigator 1 AbbVie, Inc. $18,690.98 04/22/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586531
Principal investigator 1 AstraZeneca UK Limited $5,994.90 04/18/2019 Non-covered Recipient Entity
Meridien Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685000629
Principal investigator 1 SANOFI US SERVICES INC. $2,600.00 04/18/2019 Non-covered Recipient Entity
Meridien Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691554288
Principal investigator 1 AbbVie, Inc. $4,584.25 04/16/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586533
Principal investigator 1 Avanir Pharmaceuticals, Inc. $15,392.25 04/11/2019 Non-covered Recipient Entity
MERIDIAN RESEARCH, INC
15-AVP-786-302 No dispute reported 06/30/2026 656018099
Principal investigator 1 Eisai Inc. $1,658.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525149
Principal investigator 1 Eisai Inc. $1,120.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525151
Principal investigator 1 Eisai Inc. $1,190.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525153
Principal investigator 1 Eisai Inc. $1,859.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525155
Principal investigator 1 Eisai Inc. $75.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525157
Principal investigator 1 Eisai Inc. $605.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525159
Principal investigator 1 Eisai Inc. $75.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525161
Principal investigator 1 Eisai Inc. $382.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525163
Principal investigator 1 Eisai Inc. $75.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525165
Principal investigator 1 Eisai Inc. $1,600.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525167
Principal investigator 1 Eisai Inc. $3,802.00 04/04/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525169
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $1,750.00 04/03/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH - SAINT PETERSBURG FL
SOBI.ANAKIN-401 No dispute reported 06/30/2026 700033515
Principal investigator 1 SANOFI US SERVICES INC. $700.00 03/28/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691550397
Principal investigator 1 AbbVie, Inc. $25,118.96 03/22/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586523
Principal investigator 1 AbbVie, Inc. $421.20 03/15/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586521
Principal investigator 1 Eisai Inc. $1,658.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525077
Principal investigator 1 Eisai Inc. $1,120.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525079
Principal investigator 1 Eisai Inc. $1,600.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525081
Principal investigator 1 Eisai Inc. $1,859.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525083
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525085
Principal investigator 1 Eisai Inc. $605.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525087
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525089
Principal investigator 1 Eisai Inc. $1,658.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525091
Principal investigator 1 Eisai Inc. $1,658.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525093
Principal investigator 1 Eisai Inc. $1,658.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525095
Principal investigator 1 Eisai Inc. $2,002.00 03/12/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH INC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525097
Principal investigator 1 SANOFI US SERVICES INC. $4,297.00 02/28/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691546399
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $473.57 02/19/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH - SAINT PETERSBURG FL
SOBI.ANAKIN-401 No dispute reported 06/30/2026 700033451
Principal investigator 1 AbbVie, Inc. $350.00 02/14/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586517
Principal investigator 1 SANOFI US SERVICES INC. $780.00 02/12/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691547945
Principal investigator 1 SANOFI US SERVICES INC. $5,132.00 02/11/2019 Non-covered Recipient Entity
Meridien Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691547621
Principal investigator 1 SANOFI US SERVICES INC. $1,445.00 02/11/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691547625
Principal investigator 1 AbbVie, Inc. $500.00 02/08/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586519
Principal investigator 1 AbbVie, Inc. $526.50 01/28/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586525
Principal investigator 1 SANOFI US SERVICES INC. $1,113.00 01/22/2019 Non-covered Recipient Entity
Meridien Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691547893
Principal investigator 1 AbbVie, Inc. $10,407.68 01/18/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586527
Principal investigator 1 Amgen Inc. $14,850.00 01/11/2019 Non-covered Recipient Entity
MERIDIEN RESEARCH
GOULD No dispute reported 06/30/2026 675787785
Principal investigator 1 OPKO Pharmaceuticals, LLC $33,843.70 01/10/2019 Non-covered Recipient Entity
Meridien Research, Inc.
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 704259967
Principal investigator 1 AbbVie, Inc. $1,500.00 01/07/2019 Non-covered Recipient Entity
Meridien Research
M16-100 No dispute reported 06/30/2026 647586529